Testimony of
David R. Gaugh, RPh
Senior Vice President, Sciences & Regulatory Affairs
Association for Accessible Medicines

Before the
Subcommittee on Health
of the House Committee on Energy and Commerce

“FDA User Fee Reauthorization:
Ensuring Safe and Effective Drugs and Biologics”

February 3, 2022
Chairwoman Eshoo, Ranking Member Guthrie and Members of the Subcommittee:

Thank you for holding today’s hearing on the reauthorization of the Food and Drug Administration’s (FDA) user fee programs and for the opportunity to testify about the critical role the Generic Drug User Fee Amendments (GDUFA) and the Biosimilar User Fee Act (BsUFA) hold in increasing patient access to more affordable generic and biosimilar medicines. My name is David Gaugh, Senior Vice President for Sciences and Regulatory Affairs at the Association for Accessible Medicines (AAM). I am a licensed pharmacist with more than two decades of experience working in and around the generic drug industry, and I represented the industry in the initial development and in both subsequent renewals of the generic and biosimilar user fee agreements.

AAM and its Biosimilar Council are the nation’s leading trade association for the manufacturers and distributors of FDA-approved generic and biosimilar prescription medicines. Today, generic and biosimilar medicines comprise 90% of prescriptions in the United States at only 18% of total drug spending. AAM’s members provide more than 52,000 jobs at nearly 150 facilities and manufacture more than 60 billion doses of generic medicines in the United States every year. Our core mission is to improve lives by advancing timely access to high-quality, more affordable safe and effective generic and biosimilar medicines.

In today’s testimony, I will highlight the success of the FDA’s generic and biosimilar programs in significantly increasing patient access to lower-cost medicines and, in turn, dramatically lowering the cost of prescription drugs for America’s patients and our health care system over the last 10 years; outline the improvements made to the public-private partnership embodied in GDUFA III and BsUFA III; and discuss how congressional approval of the FDA user fee programs for the next five years (FY2023-2027) will benefit patients and increase their access to more affordable treatments.

AAM and its Biosimilars Council strongly support congressional reauthorization of GDUFA and BsUFA as negotiated and without changes. Timely approval of the FDA user fee agreements ensures patients will continue to benefit from new, more affordable generic and biosimilar medicines.

**GDUFA and BsUFA at 10 Years**

Ten years ago, Congress created the FDA’s user fee programs for generic and biosimilar medicines when it enacted GDUFA and BsUFA as part of the FDA Safety and Innovation Act of 2012. For generic drugs, the number of applications submitted to the FDA had increased substantially since enactment of the Hatch-Waxman Act. Prior to GDUFA, FDA’s review of abbreviated new drug applications (ANDA) was often slow and

---


unpredictable. For biosimilar medicines, FDA’s licensure pathway for these new treatments had been created in 2010 as part of the Biologics Price Competition and Innovation Act (BPCIA). With passage of the first GDUFA and BsUFA iterations in 2012, Congress helped ensure FDA would have sufficient resources to carry out its mission.

Congressional authorization of the FDA’s generic and biosimilar user fee programs in 2012 and reauthorization in 2017 substantially increased the resources available to the Agency to review applications. More than $4 billion in supplemental user fees from generic and biosimilar developers was and will be provided as a result.³

### Generic and Biosimilar User Fee Collections
**CY2013-2021**

<table>
<thead>
<tr>
<th>Year</th>
<th>GDUFA I &amp; BsUFA</th>
<th>GDUFA II &amp; BsUFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>$298</td>
<td>$1.5</td>
</tr>
<tr>
<td>2014</td>
<td>$322</td>
<td>$2.4</td>
</tr>
<tr>
<td>2015</td>
<td>$294</td>
<td>$3.0</td>
</tr>
<tr>
<td>2016</td>
<td>$233</td>
<td>$3.5</td>
</tr>
<tr>
<td>2017</td>
<td>$333</td>
<td>$4.0</td>
</tr>
<tr>
<td>2018</td>
<td>$432</td>
<td>$4.5</td>
</tr>
<tr>
<td>2019</td>
<td>$335</td>
<td>$5.0</td>
</tr>
<tr>
<td>2020</td>
<td>$339</td>
<td>$5.5</td>
</tr>
<tr>
<td>2021</td>
<td>$429</td>
<td>$6.0</td>
</tr>
<tr>
<td>2022</td>
<td>$432</td>
<td>$6.5</td>
</tr>
</tbody>
</table>

With the additional resources, FDA was able to increase efficiencies and approval of generic drugs increased significantly, with full and tentative approvals exceeding 1,000 in fiscal years 2017, 2018 and 2019. The median number of ANDA approvals has increased over time as a result of GDUFA I and GDUFA II.⁴ The partnership between FDA and the generic industry has enhanced the overall stability and predictability of the GDUFA program and accelerated the timely review of ANDAs, increasing access to quality affordable generic medicines.

---


Following the creation of the biosimilars pathway and subsequent development of the biosimilars program, FDA licensed the first biosimilar in 2015 and has now licensed 33 biosimilars in the U.S.\textsuperscript{5} Biosimilar medicines are safe, effective and more affordable treatments for patients and, with 21 products launched and available to patients, biosimilars are already delivering on their promise of lower costs and expanded patient access to care.

\textbf{Biosimilar Approvals}
\textit{2013-2021}

\textsuperscript{5} Biosimilars Council, “FDA Biosimilars Approvals,” December 2021 (\textcolor{blue}{link}).
With FDA approval, the introduction of new generic and biosimilar medicines leads to competition in the pharmaceutical market – and the result is a significant reduction in the cost of prescription drugs for patients. Experience shows drug prices decline rapidly when generics enter the market. According to FDA, prices fall as generics enter the market – by an average of 39% when there is only one generic and by nearly 80% when four or more generics enter the market. Evidence with biosimilar medicines is similar with an average cost savings of 45%. Importantly, biosimilar competition also results in lower brand biologic costs – by about 25% on average.

Over the last 10 years, generics and biosimilars provided more than $2 trillion in savings – including $469 billion from new generics and more than $12 billion from biosimilars – to patients and the U.S. health care system. In addition to the cost savings provided, patient access to life-saving treatments is broadened as the price of medicine falls. A recent analysis of Medicare Part D from the Congressional Budget Office noted “the number of standardized prescriptions dispensed for generic drugs more than doubled from 2009 through 2018.”

### Annual Savings from Generics and Biosimilars ($ Billion)

![Annual Savings from Generics and Biosimilars](chart)

---


8 AAM Analysis of Average Sales Price Files, January 2022.

9 Ibid.

10 Ibid., AAM Generic & Biosimilar Savings Report.

GDUFA and BsUFA aim to put FDA’s generic and biosimilar drug programs on firm financial footing by enabling FDA to assess user fees to fund critical and measurable enhancements and, in turn, bringing greater predictability and timeliness to the review of applications. As a direct outcome, the generic and biosimilar drug programs have increased patient access to safe, effective and affordable quality medicines.

**GDUFA III Enhancements**

FDA plays a critically important role in making lower-cost, high-quality generic medicines available to patients. FDA reviews ANDAs submitted by generic drug manufacturers (ANDA sponsors). To receive FDA approval, data submitted in an ANDA must generally demonstrate that the generic drug is bioequivalent to the Reference Listed Drug (RLD), more commonly known as the innovator or brand product.

The GDUFA commitment letter specifies various fees the FDA sets and can collect from manufacturers, such as ANDA applications, Drug Master Files (DMF), and facility and program fees.\(^{12}\) The fees paid by the generic drug industry aid FDA’s ability to meet agreed-upon performance goals and commitments, such as timely reviews and other regulatory activities. FDA also provides annual reports to Congress on its performance.\(^{13}\) The increases in transparency and communication are important to FDA’s ability to meet the commitments, which enhance the overall stability and predictability of the GUDFA program.

The GDUFA III negotiated commitments will further strengthen and build upon the progress made and lessons learned from GDUFA I and GDUFA II. Let me take a moment to highlight five areas – advancing approvals, complex generics, inspections, suitability petitions and sustainability – where we believe the FDA’s generic drug program will be enhanced with congressional ratification of GDUFA III.

**Advancing Approvals**

GDUFA III includes important commitments that will maintain FDA’s rigorous ANDA review standards, building upon and improving the review process to increase timely patient access to high-quality, lower-cost generic medicines. For example, the newly negotiated provision known as “imminent action” will allow the FDA to extend a goal date by up to 60 days if in FDA’s judgment an approval or tentative approval of the application is imminent. This commitment will mitigate the need to add additional review cycles unnecessarily and delay approvals over minor, easily resolvable issues.

\(^{12}\) AAM, “The Generic Drug User Fee Amendments (GDUFA III),” October 2021 (link); FDA, “GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027,” October 2021 (link).

\(^{13}\) FDA, GDUFA Performance Reports, FY2015 – FY2020 (link).
**Complex Generics**

Complex generics are generic versions of brand-name drugs that have complex active ingredients, routes of administration, drug-device combinations or formulations. These drugs are more difficult to develop due in part to the lack of FDA product-specific guidance. Congress and FDA helped spur competition for complex products by including provisions in the previous user fee authorizations to increase product-specific guidance publication and meetings with FDA during the product development phase. GDUFA III builds on this success through commitments to facilitate the development and publication of product-specific guidances for complex generic products – increasing transparency and understanding of FDA’s expectations to allow for a more predictable review process.

**Inspections**

Generic and biosimilar developers support FDA’s inspections program. One of the original purposes of GDUFA was to provide resources for FDA to conduct facility inspections. Under the inspections process, FDA typically inspects a facility and identifies deficiencies. The facility has a specified timeframe to address and correct the identified deficiencies and subsequently request a reinspection from FDA. In some cases, extended time passes from when a facility performs the corrective actions to resolve the deficiencies and the time period when FDA can reinspect. Delays in reinspection lead to significant delays in the review process. GDUFA III enhances the efficiencies of the inspection process by helping ensure reinspection occurs within a specified timeframe.

**Suitability Petitions**

Suitability petitions are required to be submitted to FDA when a generic drug manufacturer intends to seek approval of an ANDA for a drug that differs from the reference brand product in terms of the active ingredient (for a combination product), route of administration, strength and/or dosage form. Current law requires FDA to grant or deny suitability petitions within 90 days from petition submission. That deadline, however, is rarely met. This results in delays to generic market entry. GDUFA III includes commitments and resources to facilitate the FDA’s ability to conduct a timely review of suitability petitions. These new resources will help FDA meet GDUFA III commitments, including conducting completeness assessments within 21 days from petition submission and using agreed upon metrics to prioritize petition reviews.

**Sustainability of Resources**

Under GDUFA II, FDA committed to developing a Resource Capacity Planning (RCP) capability to optimize resources and better anticipate future resource needs. GDUFA III provides an additional tool to further enhance the utility of the RCP to allow FDA to better forecast resource needs via the Capacity Planning Adjustment (CPA). The CPA will help promote sustainability for both FDA and industry by allowing FDA to increase full-time employee needs as workload increases. In turn, the CPA will provide
predictability for generic developers through a 3% cap to prevent significant fluctuation in fees and minimize the financial barriers for smaller generic manufacturers.

**BsUFA III Enhancements**

Similar to FDA’s generic drug program, FDA helps ensure America’s patients gain access to high-quality, more affordable biological products in the form of biosimilars. FDA reviews abbreviated biologics license applications (BLA) submitted by biosimilar developers. In order for a biosimilar to be licensed, data submitted in a BLA must demonstrate the biosimilar drug product is “highly similar” to the brand-name reference biologic and there are no clinically meaningful differences in safety, purity or potency.

BsUFA allowed FDA to assess and collect fees from developers and manufacturers that submit BLAs for FDA’s review. The negotiated commitments enhance and improve the review process to facilitate timely access to biosimilar medicines and ensures the Agency has the necessary resources to fulfill the agreed upon commitments. FDA also provides annual reports to Congress on its performance.14

The BsUFA III negotiated agreement will further strengthen and build upon the progress made and lessons learned from BsUFA I and BsUFA II.15 Let me highlight several enhancements to FDA’s biosimilars program – supplement reviews, meeting management, regulatory science and interchangeability, inspections, use of carryover funds and IT modernization. I will briefly describe each.

**BLA Supplements**

Biosimilar developers can submit supplements to modify an approved BLA, for example, updating labeling with new safety information or changes to indications. Under BsUFA III, FDA commits to accelerating supplement reviews for safety labels, extrapolation, label carve-in and carve-outs and new pharmacokinetic data.

**Meeting Management**

Biosimilar developers participate in meetings with FDA to gain insight into the agency’s expectations and perspectives on different issues. These meetings help facilitate a predictable and efficient review process. BsUFA III includes commitments to: add a new type of meeting to get feedback on focused questions; make meetings more efficient; help provide FDA with sufficient information in advance of meetings; and obtain rapid clarification of meeting minutes.

---

14 FDA, BsUFA Performance Reports, FY2013 – FY2020 (link).

15 AAM, “Key Elements of BsUFA III,” September 2021 (link); FDA, “Biosimilar Biological Product Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027,” September 2021 (link).


**Regulatory Science and Interchangeability**

As of January 2022, FDA has licensed two interchangeable biosimilars. In order to achieve the interchangeable designation, a biosimilar must produce the same clinical result as the brand-name biologic. With the interchangeable designation and subject to state law, a pharmacist may dispense an interchangeable biosimilar when a brand-name biologic is prescribed without intervention from the provider. BsUFA III will help manufacturers to develop more interchangeable biosimilars through the new Regulatory Science Program’s demonstration project. These demonstration projects will also evaluate mechanisms to streamline overall biosimilar development. Findings from the demonstration projects will inform a comprehensive strategy to advance interchangeability and the development of future guidance documents.

**Remote Inspections**

FDA uses alternate tools to conduct inspections and supplement its ability to assess manufacturing facilities remotely. Due to the COVID-19 pandemic, FDA used these alternate tools to request records and documentation from its regulatory partners. Under BsUFA III, FDA commits to issuing guidance on the use of alternative tools.

**Use of Carryover Funds**

Any remaining user fees collected by FDA but not yet spent are carried over to the next year. Under BsUFA III, FDA commits to reducing the carryover balance from 39 weeks to 21 weeks over a three-year period.

**IT Modernization**

FDA continues to modernize the Agency’s IT capabilities. BsUFA III will further FDA’s efforts. For example, FDA will modernize and move the Electronic Submissions Gateway to the cloud to help improve transparency and communication.

**Conclusion**

Patient access to generic and biosimilar medicines has never been more critical. Over the last 10 years, GDUFA and BsUFA significantly increased the resources available to FDA for review of generic and biosimilar applications. The benefit of this partnership between FDA and industry is clear: record levels of generic drugs were approved in 2017-2019 and more than 30 biosimilar medicines were licensed. The end result is lower prescription drug costs for America’s patients. Since the establishment of FDA’s generic and biosimilar programs in 2012, patients and the U.S. health care system have saved more than $2 trillion – including $469 billion from new generics and more than $12 billion from biosimilars. Congressional passage of GDUFA and BsUFA, along with their reauthorization in 2017, made this possible.
GDUFA III and BsUFA III build on this success. The user fee agreements incorporate lessons learned, include enhancements to ensure the timely review of applications and provide FDA with sufficient resources over the next five years (FY23-27). GDUFA III and BsUFA III are the culmination of months of negotiations, have been subject to public review and comment, and represent a careful balance between stakeholders. AAM and its Biosimilars Council strongly support congressional reauthorization of GDUFA and BsUFA as negotiated and without changes. Timely approval of the FDA user fee agreements ensures patients will continue to benefit from new, high-quality and more affordable generic and biosimilar medicines. We look forward to working with members of both parties to accomplish this goal.

Thank you again for the opportunity to testify on this important issue. I look forward to answering your questions.